Gossamer Bio Starts Off Well, Trades 12% Above IPO Price On Day One

San Diego, CA: Upcoming biopharmaceutical firm, Gossamer Bio (NASDAQ:GOSS) had its debut on the NASDAQ on Friday, February 8th, 2019 and managed to carry out nicely. The immunology and oncology targeted participant had set its situation value at $16 per share, whereas providing 17.25 million shares to boost $276 million for funding its analysis for the aim of discovering, buying, creating and commercializing therapeutics.

Gossamer Bio’s stock opened as excessive as $19 per share on Friday however later witnessed a slight fall. It closed the day at a value of $17.75 which is 12.13% above its IPO value. The optimism surrounding the corporate is essentially a operate of the truth that it has a good pipeline which incorporates the GB001 drug, targeted on curing average to extreme eosinophilic bronchial asthma. The drug is at present on Phase 2b of medical trials since October 2018 and two of its different medication are nonetheless in Phase 1 which suggests that the corporate will proceed to be at zero-revenues for a protracted time period earlier than having the ability to monetize this analysis. The administration has not fashioned any sort of partnership with different pharmaceutical or biotech giants both which is one other crimson flag in opposition to the stock.

Gossamer Bio acquired its final spherical of funding of about $230 million from ARCH Venture Partners and Omega Funds who’re two of its largest shareholders. Given the present standing of its drug pipeline, it’s evident that the corporate will require a number of rounds of funding sooner or later even after the $276 million from the IPO and the $230 million of personal funding earlier than the administration is in a position to start displaying some optimistic revenues. There is predicted to be little optimism surrounding the stock till the GB001 trials start progressing quickly.


This website is a wholly owned subsidiary of SCD Media, LLC, herein referred to as Smallcaps Daily. Our publications are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We may receive compensation for this article on a PPC basis as an affiliate. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. PLEASE NOTE WELL: Smallcaps Daily and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.Release of Liability: Through use of this website viewing or using you agree to hold Smallcaps Daily, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Smallcaps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Smallcaps Daily makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Smallcaps Daily strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Smallcaps Daily is compliant with the Can Spam Act of 2003. Salesparq, LLC does not offer such advice or analysis, and Smallcaps Daily further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.In preparing this publication, Smallcaps Daily, has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. Smallcaps Daily has not been compensated for this article. The advertisements in this website are believed to be reliable, however, Smallcaps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Smallcaps Daily is not responsible for any claims made by the companies advertised herein, nor is Smallcaps Daily responsible for any other promotional firm, its program or its structure. Smallcaps Daily is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Show More

Related Articles

Back to top button